Timing of bisphosphonate (Alendronate) initiation after surgery for fragility fracture: A population-based cohort study

Meng Huang Wu, Yu Sheng Lin, Christopher Wu, Ching Yu Lee, Yi Chia Chen, Tsung Jen Huang, Jur Shan Cheng

研究成果: 雜誌貢獻文章同行評審

摘要

Bisphosphonates are used as first-line treatment for the prevention of fragility fracture (FF); they act by inhibiting osteoclast-mediated bone resorption. The timing of their administration after FF surgery is controversial; thus, we compared the incidence of second FF, surgery for second FF, and adverse events associated with early initiation of bisphosphonates (EIBP, within 3 months of FF surgery) and late initiation of bisphosphonates (LIBP, 3 months after FF surgery) in bisphosphonate-naïve patients. This retrospective population-based cohort study used data from Taiwan’s Health and Welfare Data Science Center (2004–2012). A total of 298,377 patients received surgeries for FF between 2006 and 2010; of them, 1209 (937 EIBP and 272 LIBP) received first-time bisphosphonates (oral alendronate, 70 mg, once a week). The incidence of second FF (subdistribution hazard ratio (SHR) = 0.509; 95% confidence interval (CI): 0.352–0.735), second FF surgery (SHR = 0.452; 95% CI: 0.268–0.763), and adverse events (SHR = 0.728; 95% CI: 0.594–0.893) was significantly lower in the EIBP group than in the LIBP group. Our findings indicate that bisphosphonates should be initiated within 3 months after surgery for FF.

原文英語
文章編號2541
期刊Journal of Clinical Medicine
10
發行號12
DOIs
出版狀態已發佈 - 6月 2 2021

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Timing of bisphosphonate (Alendronate) initiation after surgery for fragility fracture: A population-based cohort study」主題。共同形成了獨特的指紋。

引用此